Literature DB >> 15367687

The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells.

Masashi Akaike1, Wenyi Che, Nicole-Lerner Marmarosh, Shinsuke Ohta, Masaki Osawa, Bo Ding, Bradford C Berk, Chen Yan, Jun-ichi Abe.   

Abstract

Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription factors that form a subfamily of the nuclear receptor gene family. Since both flow and PPARgamma have atheroprotective effects and extracellular signal-regulated kinase 5 (ERK5) kinase activity is significantly increased by flow, we investigated whether ERK5 kinase regulates PPARgamma activity. We found that activation of ERK5 induced PPARgamma1 activation in endothelial cells (ECs). However, we could not detect PPARgamma phosphorylation by incubation with activated ERK5 in vitro, in contrast to ERK1/2 and JNK, suggesting a role for ERK5 as a scaffold. Endogenous PPARgamma1 was coimmunoprecipitated with endogenous ERK5 in ECs. By mammalian two-hybrid analysis, we found that PPARgamma1 associated with ERK5a at the hinge-helix 1 region of PPARgamma1. Expressing a hinge-helix 1 region PPARgamma1 fragment disrupted the ERK5a-PPARgamma1 interaction, suggesting a critical role for hinge-helix 1 region of PPARgamma in the ERK5-PPARgamma interaction. Flow increased ERK5 and PPARgamma1 activation, and the hinge-helix 1 region of the PPARgamma1 fragment and dominant negative MEK5beta significantly reduced flow-induced PPARgamma activation. The dominant negative MEK5beta also prevented flow-mediated inhibition of tumor necrosis factor alpha-mediated NF-kappaB activation and adhesion molecule expression, including vascular cellular adhesion molecule 1 and E-selectin, indicating a physiological role for ERK5 and PPARgamma activation in flow-mediated antiinflammatory effects. We also found that ERK5 kinase activation was required, likely by inducing a conformational change in the NH(2)-terminal region of ERK5 that prevented association of ERK5 and PPARgamma1. Furthermore, association of ERK5a and PPARgamma1 disrupted the interaction of SMRT and PPARgamma1, thereby inducing PPARgamma activation. These data suggest that ERK5 mediates flow- and ligand-induced PPARgamma activation via the interaction of ERK5 with the hinge-helix 1 region of PPARgamma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367687      PMCID: PMC516745          DOI: 10.1128/MCB.24.19.8691-8704.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  39 in total

1.  The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors.

Authors:  X Hu; M A Lazar
Journal:  Nature       Date:  1999-11-04       Impact factor: 49.962

2.  Characterization of the repressor function of the nuclear orphan receptor retinoid receptor-related testis-associated receptor/germ cell nuclear factor.

Authors:  Z Yan; A M Jetten
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

Review 3.  Inflammatory pathways in atherosclerosis and acute coronary syndromes.

Authors:  J Plutzky
Journal:  Am J Cardiol       Date:  2001-10-18       Impact factor: 2.778

4.  Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding.

Authors:  P Pissios; I Tzameli; P Kushner; D D Moore
Journal:  Mol Cell       Date:  2000-08       Impact factor: 17.970

5.  Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

Authors:  A R Collins; W P Meehan; U Kintscher; S Jackson; S Wakino; G Noh; W Palinski; W A Hsueh; R E Law
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

6.  Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains.

Authors:  C Yan; H Luo; J D Lee; J Abe ; B C Berk
Journal:  J Biol Chem       Date:  2001-01-03       Impact factor: 5.157

7.  Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

Authors:  A C Li; K K Brown; M J Silvestre; T M Willson; W Palinski; C K Glass
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

8.  ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain.

Authors:  H G Kasler; J Victoria; O Duramad; A Winoto
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

9.  PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.

Authors:  N Marx; T Bourcier; G K Sukhova; P Libby; J Plutzky
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

10.  Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species.

Authors:  M Yoshizumi; J Abe; J Haendeler; Q Huang; B C Berk
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

View more
  61 in total

1.  PKCzeta decreases eNOS protein stability via inhibitory phosphorylation of ERK5.

Authors:  Patrizia Nigro; Jun-ichi Abe; Chang-Hoon Woo; Kimio Satoh; Carolyn McClain; Michael R O'Dell; Hakjoo Lee; Jae-Hyang Lim; Jian-dong Li; Kyung-Sun Heo; Keigi Fujiwara; Bradford C Berk
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  Disturbed-flow-mediated vascular reactive oxygen species induce endothelial dysfunction.

Authors:  Kyung-Sun Heo; Keigi Fujiwara; Jun-ichi Abe
Journal:  Circ J       Date:  2011-11-10       Impact factor: 2.993

3.  UAP56 is an important regulator of protein synthesis and growth in cardiomyocytes.

Authors:  Abha Sahni; Nadan Wang; Jeffrey D Alexis
Journal:  Biochem Biophys Res Commun       Date:  2010-01-29       Impact factor: 3.575

Review 4.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

5.  Novel role of C terminus of Hsc70-interacting protein (CHIP) ubiquitin ligase on inhibiting cardiac apoptosis and dysfunction via regulating ERK5-mediated degradation of inducible cAMP early repressor.

Authors:  Chang-Hoon Woo; Nhat-Tu Le; Tetsuro Shishido; Eugene Chang; Hakjoo Lee; Kyung-Sun Heo; Deanne M Mickelsen; Yan Lu; Carolyn McClain; Thomas Spangenberg; Chen Yan; Carlos A Molina; Jay Yang; Cam Patterson; Jun-ichi Abe
Journal:  FASEB J       Date:  2010-08-19       Impact factor: 5.191

Review 6.  Vascular shear stress and activation of inflammatory genes.

Authors:  Cameron J World; Gwenaele Garin; Bradford Berk
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

Review 7.  PPARs and molecular mechanisms of transrepression.

Authors:  Mercedes Ricote; Christopher K Glass
Journal:  Biochim Biophys Acta       Date:  2007-03-12

Review 8.  Coordination of Cellular Localization-Dependent Effects of Sumoylation in Regulating Cardiovascular and Neurological Diseases.

Authors:  Jun-Ichi Abe; Uday G Sandhu; Nguyet Minh Hoang; Manoj Thangam; Raymundo A Quintana-Quezada; Keigi Fujiwara; Nhat Tu Le
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

9.  De-SUMOylation enzyme of sentrin/SUMO-specific protease 2 regulates disturbed flow-induced SUMOylation of ERK5 and p53 that leads to endothelial dysfunction and atherosclerosis.

Authors:  Kyung-Sun Heo; Eugene Chang; Nhat-Tu Le; Hannah Cushman; Edward T H Yeh; Keigi Fujiwara; Jun-ichi Abe
Journal:  Circ Res       Date:  2013-02-04       Impact factor: 17.367

10.  A crucial role for p90RSK-mediated reduction of ERK5 transcriptional activity in endothelial dysfunction and atherosclerosis.

Authors:  Nhat-Tu Le; Kyung-Sun Heo; Yuichiro Takei; Hakjoo Lee; Chang-Hoon Woo; Eugene Chang; Carolyn McClain; Cheryl Hurley; Xin Wang; Faqian Li; Haodong Xu; Craig Morrell; Mark A Sullivan; Michael S Cohen; Iana M Serafimova; Jack Taunton; Keigi Fujiwara; Jun-Ichi Abe
Journal:  Circulation       Date:  2012-12-14       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.